Regulatory & Legal

Industry legend William Sheriff moves to Verdera Energy, unlocking a major New Mexico uranium portfolio in a strategic spin-out from giant enCore Energy.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.

Following strong shareholder support, Azimut Exploration launches a massive drilling campaign targeting deep gold potential and expanding known resources in Quebec.

As childhood nearsightedness soars, a new contact lens offers hope by not just correcting vision but actively slowing its progression in key global markets.

Nova Minerals confirms a major gold-copper system at its Estelle Project, with high-grade samples boosting US critical mineral prospects and exciting investors.

Hopes for a new Huntington's gene therapy face a major delay as the FDA rejects uniQure's current data and calls for a more rigorous, complex study.

Riding record gold prices, TRX Gold shatters production records and cleans its balance sheet, fast-tracking a major expansion at its Buckreef project.

Zymeworks lands $250M from Royalty Pharma in a non-dilutive deal, validating its cancer drug Ziihera and highlighting a new era of biotech financing.

With star-studded advisory board, a new biotech firm aims to turn routine dental visits into a frontline defense against oral cancer.

A Chinese firm's 'Global Pioneer' status in cellular essence sparks debate on the future of biotech in cosmetics, medicine, and global regulation.

Helios Consortium's formal offer for CAB Payments is rejected as 'opportunistic,' igniting a battle for control of the emerging markets payment specialist.

Activist fund GAM escalates its fight in Japan, filing an injunction to stop a Honda-backed squeeze-out it claims values a key auto parts business at zero.

At the India AI Impact Summit, experts warned that AI crises will move at machine speed. Can global diplomacy and safety protocols catch up before it's too late?

Shareholder approval paves the way for cancer therapy innovator VERAXA to go public, aiming to accelerate its next-gen antibody-drug conjugate pipeline.

With its new AI thriller, muVpix is betting on 'engineered storytelling' to finally crack the vertical video code that doomed giants like Quibi.

Canada’s ambitious high-speed rail plan is facing fierce opposition from farmers who say the project threatens their land, livelihood, and food security.

A $4.4 million inventory write-down plunges the world's first private cord blood bank into the red, raising questions about its public banking model.

Healthpeak Properties is launching a new senior housing REIT, Janus Living. What does this strategic pivot mean for investors and the real estate market?

In a radical pivot, diagnostics firm OpGen has become CapForce, an AI-powered investment bank targeting a $10B niche. Can it trade microbes for money?

SmartCentres REIT pushes back a key deadline with its CEO's private firm, spotlighting a complex web of strategy, governance, and founder influence.